Characterization of Early Plasma Concentrations of Midazolam in Pigs After Administration by an Autoinjector

Total Page:16

File Type:pdf, Size:1020Kb

Characterization of Early Plasma Concentrations of Midazolam in Pigs After Administration by an Autoinjector BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 25: 297–301 (2004) Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.417 Characterization of Early Plasma Concentrations of Midazolam in Pigs after Administration by an Autoinjector Aharon Levy*, Moshe Kushnir, Shira Chapman, Rachel Brandeis, Zvi Teitelbaum and Eran Gilat Department of Pharmacology, Israel Institute for Biological Research, Ness Ziona, POB 19, 74100, Israel ABSTRACT: The treatment of organophosphate-induced poisoning is based mainly on atropine and an oxime. Prompt anticonvulsive intervention is usually also required to terminate the ensuing seizure activity and to prevent delayed permanent brain damage. Midazolam, a water-soluble benzodiazepine agonist, has the advantage of rapid absorption following intramuscular administration. In mass casualty situations, the availability of an autoinjector, filled with midazolam, might be a further advantage. In the present study, the plasma pharmacokinetics of midazolam after administration by an autoinjector was compared with conventional intramuscular (i.m.) administration in two groups of four pigs each. During the first 15 min after injection, significantly higher plasma concentrations of midazolam were detected following autoinjector administration, compared with the i.m. injection. The physiological reflection of the accelerated midazolam absorption was a marked reduction in the time interval required for muscle relaxation, induced by midazolam. It is concluded that a midazolam autoinjector might be helpful in the mass casualty scenario following organophosphate poisoning. Copyright # 2004 John Wiley & Sons, Ltd. Key words: anticonvulsants; benzodiazepines; organophosphates; sedation; seizures Introduction soluble benzodiazepine agonist, has the advan- tage of a higher bioavailability and a more rapid One of the most important elements for the absorption and onset of activity, following successful treatment of organophosphate (OP) intramuscular (i.m.) administration [6]. There- cholinesterase-inhibitor poisoning is its prompt fore, the drug has been suggested as a possible application. While traditional routine therapy is replacement for diazepam in the US army [7]. based on the administration of the muscarinic Midazolam has a further advantage when ad- blocker atropine and an oxime that reactivates ministered through the nasal route [8,9], the inhibited enzyme, rapid intervention with an although at this point, at least for battlefield anticonvulsant for the quick termination of application, this route does not seem practical seizure activity is also often required [1,2]. yet. In a comparison between the various Inefficient or delayed anticonvulsive treatment benzodiazepines for the control of soman- may lead to permanent brain damage [3–5]. induced seizures in guinea-pigs, midazolam was Diazepam (or its pro-drug avizafone) is used in found to be the most potent and rapidly acting the treatment strategy of various countries. [10]. Midazolam also had a better performance Compared with diazepam, midazolam, a water- when compared with diazepam in monkeys [11]. A few papers in the literature reported the different pharmacokinetics of drugs following *Correspondence to: Department of Pharmacology, Israel Institute for Biological Research, Ness Ziona, P.O. Box 19, 74100, Israel. intramuscular administration using an autoinjec- E-mail: [email protected] tor. In allergic children, epinephrine absorption Received 12 August 2003 Revised 27 November 2003 Copyright # 2004 John Wiley & Sons, Ltd. Accepted 10 June 2004 298 A. LEVY ET AL. was faster following injection with the automatic arrival to the Institute’s animal facility. Four EpiPen injector [12]. The time to peak concentra- comparable experiments were performed. For tion was significantly reduced compared with each experiment, one pig was injected with an subcutaneous administration, which in the case autoinjector and the other by conventional needle of anaphylaxis could be extremely important. and syringe, the pigs being matched by weight to The spring-loaded self-injector Atropen, contain- a difference not greater than 100 g. Because pigs ing the equivalent of 2 mg atropine sulfate, was grow very fast, a cross-over design was not studied in 15 healthy volunteers. It was found to possible. produce a significantly earlier increase in heart Autoinjectors, normally used for atropine, rate compared with atropine in a conventional were supplied by Shalon, Israel, each containing syringe injected i.m. [13]. In another study, the 5 mg of midazolam hydrochloride in 0.7 ml performance of an atropine autoinjector (Mark I, of saline plus preservatives. For conventional used in the US Army) was tested in 20 human i.m. injection, the content of some of these volunteers against a different injector referred to autoinjectors was released and measured. They as an MCP [14]. The Mark I injector exhibited a were found to release consistent volumes significantly higher atropine concentration in (0.734 Æ 0.002 ml n ¼ 5). Thus, using a 1 ml plasma 10 min after injection. The decrease in syringe and 23G-100 needle (identical in size to salivation was significantly more pronounced the autoinjector needle), 0.73 ml of this midazo- during the first 15 min and the increase in heart lam solution was injected i.m. into the gluteus rate was statistically significant up to 30 min muscle as a single bolus. The animals were following administration. The more rapid monitored visually, as well as physically by changes were attributed to a broader dispersion lifting their head, to determine muscle relaxation of the drug in the injected tissue. A Swedish and sedation. An ANOVA test was performed on group compared the pharmacokinetics of HI-6 the results for the ‘time to muscle relaxation’, to and atropine following injection with an Astra determine whether the differences between the Tech autoinjector to anaesthetized pigs with that two groups were statistically significant. of conventional intramuscular delivery [15]. The One ml blood samples were withdrawn from time interval for obtaining the therapeutic con- the pig subclavian vein at 1, 2, 4, 7, 10, 15, 20, 30 centration of HI-6 (defined as 4 mg/ml) was and 60 min following injection, as well as after 2, reduced from around 5 min to 1 min. 3, 4 and 5 h. Plasma was separated and kept No data are available for the pharmacokinetics frozen at À708C until assayed. of midazolam administered by autoinjectors. The Midazolam was determined by radio receptor importance of prompt anticonvulsant adminis- assay (RRA), using an adaptation of Citron’s tration after OP poisoning is the subject of the method for scopolamine [16]. Briefly, 200 mlof present study. standard midazolam samples in plasma (in the range 3.9–1000 ng/ml) were prepared and added to 5 ml of 0.05 m phosphate buffer (PB) pH 7.4. The diluted standard solutions, as well as the Materials and Methods diluted study samples, were loaded on activated Sep-Pak C18 columns (Waters, Milford MA), The study was approved by the IIBR Committee washed with 5 ml PB and then with 5 ml of for Animal Experimentation, with emphasis on double distilled water containing 20% v/v the prevention of any unnecessary animal suffer- methanol. The drug was extracted from the ing, the use of the smallest number necessary and columns with 5 ml of 100% methanol, and dried was according to the recommendations of the overnight under vacuum and centrifugation. The Guide for the Care and Use of Laboratory Animals, samples and standards were resuspended in National Academy Press, Washington DC, 1996. 200 ml of PB and 25 ml in duplicates were added White domestic young piglets (supplied by to the competitive binding mixture. [N-Methyl- Lahav, Israel), weighing around 12 kg, were used 3H]-Flunitrazepam (TRK-590, Amersham UK), throughout the study, 2–3 days following their having a specific activity of 96 Ci/mmole, served Copyright # 2004 John Wiley & Sons, Ltd. Biopharm. Drug Dispos. 25: 297–301 (2004) PLASMA CONCENTRATIONS OF MIDAZOLAM 299 as the radioactive ligand in the assay, in which 450 midazolam competed for its binding to rat brain 400 300 membranes, as described previously [16]. The 350 AUC AI=18,530±2215 ng.min/ml 300 ± minimal concentration of midazolam in the 300 AUC IM=18,550 1653 ng.min/ml SEM) standard curve, i.e. 3.9 ng/ml, determined ± 250 Autoinjector, n=4 the limit of sensitivity of the assay as seen in 200 Conventional Injection,n=4 Figure 1. Since standard solution samples were 150 (Averages always processed concomitantly with the study Midazolam (ng/ml) 100 samples in the same assay, and spiking of 50 standards in plasma gave similar results, the 0 recovery of midazolam from standards and 0 30 60 90 120 150 180 210 240 270 300 Time (min) samples was considered identical. To determine the statistical significance of the differences Figure 2. Pharmacokinetic follow-up on midazolam concen- between the two modes of injection, an ANOVA trations in plasma after autoinjector (AI) administration to pigs in comparison with conventional syringe and needle AUC test was employed and the individual injection (i.m.). Four pigs were used in each group (aver- values for each animal were compared between age Æ SEM) the two groups. two curves, using GraphPad Prism software, Results were virtually identical (18 530 Æ 2215 and 18 550 Æ 1653 ng.min/ml). Using the pharmaco- Midazolam concentrations in plasma were de- kinetic relationship Dose.F ¼ AUC.CLp, where termined at 13 time points following injection, in CLp/F represents the total plasma clearance, a four pigs for each experimental group. The clearance value of 16 l/h was obtained for these complete data are presented in Figure 2. Accord- young pigs (or approximately 1.3 l/kg.h). ing to the principles of pharmacokinetics, if Despite having similar AUCs, it was apparent the dose was indeed identical in the two that the two pharmacokinetic curves were not groups, similar areas under the curve (AUC0À300) identical. To emphasize the differences, the should be obtained.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Amperozide/Avizafone 963 Drugs of This Class, Including Aripiprazole; Most of the Deaths Ap- Antiepileptics
    Amperozide/Avizafone 963 drugs of this class, including aripiprazole; most of the deaths ap- Antiepileptics. For a report of Stevens-Johnson syndrome oc- associated with bipolar disorder in those aged 10 to 17 years. For peared due to cardiovascular events or infection. See also under curring on use of aripiprazole with lamotrigine, see p.486. both indications, the recommended initial oral dose is 2 mg daily Risperidone, p.1024. increased to 5 mg daily after 2 days and then to the target dose of The manufacturer subsequently also included a warning in the 10 mg daily after another 2 days; subsequent dose increases Pharmacokinetics should be made in 5-mg increments up to a total maximum dose licensed product information for aripiprazole about evidence of Aripiprazole is well absorbed from the gastrointestinal a dose-response relationship between cerebrovascular adverse of 30 mg daily. events and the use of aripiprazole in elderly patients with psycho- tract after oral doses with peak plasma concentrations Dose adjustments of aripiprazole may be necessary in patients sis associated with Alzheimer’s disease. reached in about 3 to 5 hours. Following intramuscular also taking potent inhibitors or inducers of cytochrome P450 1. FDA. FDA issues public health advisory for antipsychotic drugs injection, peak plasma concentrations are reached be- isoenzymes. See Interactions, above for further details. used for treatment of behavioral disorders in elderly patients (is- tween 1 to 3 hours. The absolute bioavailability is re- Psychiatric disorders. Aripiprazole is used in the manage- sued 11th April, 2005). Available at: http://www.fda.gov/bbs/ 1-9 topics/ANSWERS/2005/ANS01350.html (accessed 24/05/05) ported to be 87% with tablet formulations and 100% ment of schizophrenia (p.955) and bipolar disorder (p.372).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • PK of Medcm Against Nerve Agents, Which Have Been Integrated with PK and PD Data for the Nerve Agents Sarin and VX
    UNIVERSITY OF SOUTHAMPTON FACULTY OF MEDICINE Institute of Developmental Sciences The Pharmacokinetics of Medical Countermeasures Against Nerve Agents by Stuart Jon Armstrong Thesis for the degree of Doctor of Philosophy November 2014 UNIVERSITY OF SOUTHAMPTON ABSTRACT FACULTY OF MEDICINE Institute of Developmental Sciences Thesis for the degree of Doctor of Philosophy THE PHARMACOKINETICS OF MEDICAL COUNTERMEASURES AGAINST NERVE AGENTS Stuart Jon Armstrong Nerve agents are organophosphorus compounds that irreversibly inhibit acetylcholinesterase, causing accumulation of the neurotransmitter acetylcholine and this excess leads to an overstimulation of acetylcholine receptors. Inhalation exposure to nerve agent can be lethal in minutes and conversely, skin exposure may be lethal over longer durations. Medical Countermeasures (MedCM) are fielded in response to the threat posed by nerve agents. MedCM with improved efficacy are being developed but the efficacy of these cannot be tested in humans, so their effectiveness is proven in animals. It is UK Government policy that all MedCM are licensed for human use. The aim of this study was to test the hypothesis that the efficacy of MedCM against nerve agent exposure by different routes could be better understood and rationalised through knowledge of the MedCM pharmacokinetics (PK). The PK of MedCM was determined in naïve and nerve agent poisoned guinea pigs. PK interactions between individual MedCM drugs when administered in combination were also investigated. In silico simulations to predict the concentration-time profiles of different administration regimens of the MedCM were completed using the PK parameters determined in vivo. These simulations were used to design subsequent in vivo PK studies and to explain or predict the efficacy or lack thereof for the MedCM.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Pharmacokinetic Profile and Quantitation of Protection Against
    Toxicology Letters 244 (2016) 154–160 Contents lists available at ScienceDirect Toxicology Letters journal homepage: www.elsevier.com/locate/toxlet Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig Matthew E. Price*, Cerys J. Docx, Helen Rice, Sarah J. Fairhall, Sarah J.C. Poole, Michael Bird, Luke Whiley, Daniel P. Flint, A. Christopher Green, Christopher M. Timperley, John E.H. Tattersall Chemical, Biological and Radiological Division, Defence Science and Technology Laboratory (DSTL), Porton Down, Salisbury, Wiltshire SP4 0JQ, UK H I G H L I G H T S The bispyridinium compound MB327 protects guinea-pigs from soman poisoning. Mode of action is not reliant on reactivation of aged inhibited acetylcholinesterase. First syntheses of d6-MB327 diiodide and dimethanesulfonate salts. Used as internal standards for mass spectrometric quantitation of MB327 in guinea-pig plasma. A R T I C L E I N F O A B S T R A C T Article history: Current organophosphorus nerve agent medical countermeasures do not directly address the nicotinic Received 6 May 2015 effects of poisoning. A series of antinicotinic bispyridinium compounds has been synthesized in our Received in revised form 24 July 2015 laboratory and screened in vitro. Their actions can include open-channel block at the nicotinic receptor Accepted 10 August 2015 0 which may contribute to their efficacy. The current lead compound from these studies, MB327 1,1 - Available online 19 September 2015 (propane-1,3-diyl)bis(4-tert-butylpyridinium) as either the diiodide (I2) or dimethanesulfonate (DMS) À1 has been examined in vivo for efficacy against nerve agent poisoning.
    [Show full text]
  • List of Benzodiazepines - Wikipedia, the Free Encyclopedia
    List of benzodiazepines - Wikipedia, the free encyclopedia Log in / create account Article Talk Read Edit Our updated Terms of Use will become effective on May 25, 2012. Find out more. List of benzodiazepines From Wikipedia, the free encyclopedia Main page The below tables contain a list of benzodiazepines that Benzodiazepines Contents are commonly prescribed, with their basic pharmacological Featured content characteristics such as half-life and equivalent doses to other Current events benzodiazepines also listed, along with their trade names and Random article primary uses. The elimination half-life is how long it takes for Donate to Wikipedia half of the drug to be eliminated by the body. "Time to peak" Interaction refers to when maximum levels of the drug in the blood occur Help after a given dose. Benzodiazepines generally share the About Wikipedia same pharmacological properties, such as anxiolytic, Community portal sedative, hypnotic, skeletal muscle relaxant, amnesic and Recent changes anticonvulsant (hypertension in combination with other anti The core structure of benzodiazepines. Contact Wikipedia hypertension medications). Variation in potency of certain "R" labels denote common locations of effects may exist among individual benzodiazepines. Some side chains, which give different Toolbox benzodiazepines produce active metabolites. Active benzodiazepines their unique properties. Print/export metabolites are produced when a person's body metabolizes Benzodiazepine the drug into compounds that share a similar pharmacological
    [Show full text]